Department of Human Anatomy and Histology, University of Bari Medical School, Bari, Italy.
Cancer Chemother Pharmacol. 2011 Aug;68(2):275-8. doi: 10.1007/s00280-011-1683-z. Epub 2011 Jun 3.
It is well established that antibodies to vascular endothelial growth factor (VEGF) in combination with chemotherapeutic agents produce synergistic cytotoxicity in a range of cancer. In this review article, it has been analyzed whether the so-called vascular normalization of abnormal tumor blood vessels as an effect of VEGF inhibition in association with chemotherapeutic agents in the treatment of tumors produces a real benefit. Literature data show that the process of normalization of the structure of tumor blood vessels is not always accompanied with a real benefit. In fact as in the case of cerebral tumors, the process of normalization may induce a re-establishment of the low permeability characteristics of normal brain microvasculature, preventing the delivery of chemotherapeutics.
已经证实,血管内皮生长因子(VEGF)抗体与化疗药物联合使用,可在多种癌症中产生协同细胞毒性作用。在这篇综述文章中,分析了所谓的肿瘤血管异常的血管正常化是否作为 VEGF 抑制与化疗药物联合治疗肿瘤的一种效应,从而产生真正的益处。文献数据表明,肿瘤血管结构的正常化过程并不总是伴随着真正的益处。事实上,就像脑肿瘤的情况一样,正常化过程可能会诱导正常脑微血管的低通透性特征重新建立,从而阻止化疗药物的输送。